- Home
- ARMN vs QURE Comparison
ARMN vs QURE Comparison
Compare ARMN & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMN
- QURE
- Stock Information
- Founded
- ARMN 1992
- QURE 1998
- Country
- ARMN Canada
- QURE Netherlands
- Employees
- ARMN N/A
- QURE N/A
- Industry
- ARMN
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- ARMN
- QURE Health Care
- Exchange
- ARMN Nasdaq
- QURE Nasdaq
- Market Cap
- ARMN 769.7M
- QURE 725.4M
- IPO Year
- ARMN N/A
- QURE 2007
- Fundamental
- Price
- ARMN $6.85
- QURE $14.21
- Analyst Decision
- ARMN
- QURE Strong Buy
- Analyst Count
- ARMN 0
- QURE 10
- Target Price
- ARMN N/A
- QURE $37.20
- AVG Volume (30 Days)
- ARMN 1.6M
- QURE 1.2M
- Earning Date
- ARMN 08-12-2025
- QURE 07-31-2025
- Dividend Yield
- ARMN N/A
- QURE N/A
- EPS Growth
- ARMN 28.55
- QURE N/A
- EPS
- ARMN 0.15
- QURE N/A
- Revenue
- ARMN $560,512,000.00
- QURE $20,201,000.00
- Revenue This Year
- ARMN $49.45
- QURE $27.16
- Revenue Next Year
- ARMN N/A
- QURE $248.21
- P/E Ratio
- ARMN $43.21
- QURE N/A
- Revenue Growth
- ARMN 22.28
- QURE 6.30
- 52 Week Low
- ARMN $3.29
- QURE $3.73
- 52 Week High
- ARMN $7.01
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- ARMN 62.67
- QURE 44.61
- Support Level
- ARMN $6.61
- QURE $14.75
- Resistance Level
- ARMN $6.97
- QURE $15.35
- Average True Range (ATR)
- ARMN 0.26
- QURE 1.05
- MACD
- ARMN -0.01
- QURE -0.27
- Stochastic Oscillator
- ARMN 79.08
- QURE 10.79
About ARMN Aris Mining Corporation
Aris Mining Corp is engaged in the acquisition, exploration, development and operation of gold properties in Colombia, Guyana and Canada. It owns and operates its Segovia Operations, Soto Norte Project and Marmato Mine in Colombia, Toroparu Project in Guyana and the Juby Project in Ontario, Canada. The company generates revenue from the sale of gold and silver.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.